At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
ABC Twice Daily +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection
In Brief
A Phase 1 clinical trial evaluating ABC Twice Daily, ABC Once Daily, and 2 other interventions for HIV Infection. Completed, enrolled 19 participants across 2 sites.
Detailed Summary
Cross-over 28 week study of the plasma pharmacokinetic profiles of twice daily 3TC (4mg/kg/dose BD) with once daily 3TC (8mg/kg/dose OD) and twice daily ABC (8mg/kg/dose BD) with daily ABC (16mg/kg/dose OD) where one or both drugs are being taken as part of combination antiretroviral therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2003
Primary CompletionFeb 2004
Study CompletionMar 2004
First PostedNov 2013
TodayJul 2026
First PostedNov 13, 2013
Enrollment StartJan 1, 2003
Primary CompletionFeb 1, 2004
Study CompletionMar 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.6 years ago
Interventions
ABC Twice Dailydrug
ABC Once Dailydrug
3TC Once Dailydrug
3TC Twice Dailydrug